Diabetes pill shows promise in Real-World test
NCT ID NCT04601753
Summary
This study followed 194 adults with type 2 diabetes in Sweden who were prescribed the once-daily pill Rybelsus (oral semaglutide) by their doctors. The goal was to see how well the medication worked in everyday life to lower blood sugar levels and affect body weight over 8-10 months. Researchers collected information through doctor visits and questionnaires to understand the treatment's real-world effectiveness and patient satisfaction.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Master Centre for Sweden
Malmo, 202 15, Sweden
Conditions
Explore the condition pages connected to this study.